Alcon receives FDA approval of new multifocal IOL

April 17, 2015

Alcon Laboratories has received FDA approval for its AcrySof IQ ReSTOR +2.5 D IOL for patients undergoing cataract eye surgery who choose to address near, intermediate, and distance vision needs at the same time.

Alcon Laboratories has received FDA approval for its AcrySof IQ ReSTOR +2.5 D IOL for patients undergoing cataract eye surgery who choose to address near, intermediate, and distance vision needs at the same time.

The lens is the latest addition to Alcon’s portfolio of IOLs for cataract patients and provides an additional option to meet the visual needs of each individual patient, according to the company.


“We are pleased by the FDA’s decision,” said Sabri Markabi, senior vice president, research and development for Alcon. “This technology complements our existing AcrySof IQ ReSTOR +3.0 D IOL in the marketplace, providing more presbyopia-correcting options for ophthalmic surgeons and the patients they serve.” 


The AcrySof IQ ReSTOR +2.5 D IOL is indicated for adult patients with and without presbyopia undergoing cataract surgery who desire near, intermediate, and distance vision with increased spectacle independence.

The Centers for Medicare and Medicaid Services added the AcrySof IQ ReSTOR +2.5 D IOL to the list of CMS recognized presbyopia-correcting IOLs, confirming that AcrySof IQ ReSTOR +2.5 D IOLs will be eligible for reimbursement as both a Medicare-covered service (treatment of cataract) and as a non-covered service (presbyopia correction).

Next: more on the lens

 

The AcrySof IQ ReSTOR +2.5 D IOL will be commercially available in the United States in the near future. The product is already available in the European Union, Australia, Canada, Japan, and countries in Central and South America.